Navidea Biopharma (NAVB) Moves Higher as Insiders Buy Back In

September 14, 2012 3:31 PM EDT
Navidea Biopharmaceuticals (Nasdaq: NAVB) is higher on the session Friday amid a mix of insider buying recently.

Disclosing purchases made 12th are:
  • Director Brendan Ford - on September 12th for 5,000 shares and total cost of $13,200;

  • Director Gordon Troup bought 5,000 on August 15th and 5,000 on September 12th. The cost was $31,080;

  • CEO Mark J. Pykett acquired 4,000 on September 11th. Gross cost of $10,552; and

  • Business Chief Tom Tulip bought 15,000 shares at $2.70 for gross cost of $40,500 on September 14th.
In total, insiders disclosed the purchase of 29,000 shares.

Notably, the pharma was issued a CRL from the FDA on September 10th for Lymphoseek. Shares are down over 20 percent for the week, but up about 6 percent today.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Insider Trades, Insiders' Blog

Add Your Comment